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Summary
Type I interferons (IFN) are being rediscovered as potent anti-tumoral agents. Activation of the STimulator of INterferon Genes (STING) by DMXAA can induce a strong production of IFN and the rejection of transplanted primary tumors. In the present study, we addressed whether targeting STING with DMXAA leads to the regression of spontaneous MMTV-PyMT (Spont-PyMT) mammary tumors. We show that these tumors are refractory to DMXAA-induced regression. This is due to a blockade in the phosphorylation of IRF3 and the ensuing IFNproduction. Our study identified TGFabundant in spontaneous tumors, as a key molecule limiting DMXAA-induced tumor regression: blocking TGFpromoted infiltration of Spont-PyMT tumors by activated MHCII + tumorassociated macrophages, restored the production of IFN following STING activation, and increased the probability of tumor regression. Based on these findings, we propose that type I IFN-dependent cancer therapies may be greatly improved by combinations including the blockade of TGF.
INTRODUCTION
Type I interferon (IFN)  and  are cytokines with a great potential in anti-tumor immunity. It has been shown that endogenous type I IFN may ensure a first line of defense by innate cells, promoting an adaptive immune response not only against viruses but also against cancer cells (Diamond et al., 2011; Dunn et al., 2005; Fuertes et al., 2011) . In fact, modulation of immune responses by type I IFN may occur in several different ways. It often involves the regulation of cytokines and chemokines (CXCL10, CCL3, CCL2, IL-15), which are able to promote the recruitment, survival and activation of various immune cell subsets, including monocytes, dendritic cells (DC), T cells and NK cells.
Moreover, IFN induces the upregulation of MHC I and the acceleration of DC differentiation, thus improving the priming of T cells (Hervas-Stubbs et al., 2011; Santini et al., 2000) . In addition, the potential of IFN/to inhibit protein translation can trigger conflicting signals leading to death of highly proliferating cancer or endothelial cells (Kotredes and Gamero, 2013; Sujobert and Trautmann, 2016) .
Long recognized as broad immune modulators, type I IFN have been administered for years to treat cancer patients (Musella et al., 2017) . However, due to the toxicity induced by its systemic administration, it is no longer commonly used as such. A new enthusiasm has followed a better understanding of the mechanisms by which type I IFN modulate immune responses. Recently, the cytosolic molecule STING has been the focus of several investigations aiming at restimulating the production of type I IFN in the tumor ecosystem. STING is ubiquitously expressed and is activated by cytosolic nucleotides derived from pathogens or self-damages. In particular, it has been shown that STING can sense endogenous cytosolic DNA promoting anti-tumor immunity (Woo et al., 2014) .
Synthetic cyclic dinucleotides (CDN) injected intratumorally have been shown to elicit the generation of anti-tumor specific CD8 + T cells in vivo and the regression of transplanted tumors (Corrales et al., 2015) . Endothelial cells were found to rapidly release IFN in the tumor of transplanted tumors treated with intratumoral CDN (Demaria et al., 2015) . The DMXAA agent has the dual property of activating STING and disrupting specifically the tumor vasculature (Baguley and Siemann, 2010) . One intraperitoneal (i.p.) injection is sufficient to induce the regression of primary transplanted tumors as a single agent or in combination with vaccination ( (Fridlender et al., 2013; Henare et al., 2012; Jassar et al., 2005) . In line with this, we have recently reported that the DMXAA induced-regression of PyMT transplanted tumors relies on IFNproduction and on the cooperation of T cells with myeloid cells at the tumor site (Weiss et al., 2017) .
Together, these reports suggest that inducing type I IFN in solid tumors by targeting the STING pathway is a promising therapeutic approach. Nevertheless, would it be sufficient to induce the rejection of solid tumors that arise spontaneously? Multiple resistance mechanisms take place during the progression of spontaneous tumors, which is slower than that of transplanted ones. In particular, the transplantation of tumor cells induces an acute inflammation locally associated with cell death and priming of the immune cell infiltrate (Joncker et al., 2016) . In contrast, spontaneous tumors emerge from a sterile microenvironment exposed to a chronic inflammation likely to condition differently the immune cell infiltrate. When spontaneous tumors emerge in an animal, the T cell repertoire shaped in the thymus and the periphery gives rise to low affinity and anergic tumorinfiltrating T cells (Wang et al., 2011) . In addition, soluble factors of chronic inflammation like TGF are known to suppress various immune effector cells, modulate the profile of myeloid cells and promote the emergence of regulatory T cells. Thus, although transplanted tumors share some of the characteristics of immune suppressive environments, their rapid development, within days or weeks, do not integrate the various changes that occur in spontaneous tumors during months of development. In the MMTV-PyMT tumor model, Ming Li and colleagues have nicely described the progressive accumulation of suppressive tumor-associated macrophages (TAM) subsets in the mammary tumors from 8 week-to 20 week-old transgenic mice (Franklin et al., 2014) . In fact, the density of such TAM, assimilated to "M2-like macrophages", which represent a major component of the tumor microenvironment, has been correlated with a poor prognosis in various cancer types in humans (Zhang et al., 2012) . In contrast, detailed analyses of the myeloid cell compartment in human tumors revealed that the density of TAM with a M1-like phenotype correlate with a favorable prognosis in some cancers (Fridman et al., 2017) . In line with this, when appropriately stimulated, macrophages can mediate anti-tumor activity, together with anti-tumor CD8 + T cells, at least in transplanted tumor models (Beatty et al., 2011; Klug et al., 2013; Ma et al., 2013; Sektioglu et al., 2016; Thoreau et al., 2015; Weiss et al., 2017) . Thus, the nature and the activation status of the tumor microenvironment may drastically influence the outcome of therapeutic treatments.
In the present study, we addressed whether targeting STING with DMXAA can induce the regression of spontaneous MMTV-PyMT (Spont-PyMT) mammary tumors. We show that these tumors are refractory to DMXAA-induced regression. This is related to a blockade in the phosphorylation of IRF3 and the ensuing IFNproduction. Our study identified TGFabundant in spontaneous tumors, as a key molecule limiting DMXAA-induced tumor regression: blocking TGFpromoted infiltration of Spont-PyMT tumors by activated MHCII + TAM and restored the production of IFNfollowing STING activation.
RESULTS

Limited efficacy of DMXAA in the spontaneous MMTV-PYMT model
To assess if Spont-PYMT tumors developing in MMTV-PyMT mice could regress with a DMXAA treatment, as reported earlier for transplanted PyMT (Trans-PyMT) tumors (Weiss et al., 2017) , we injected MMTV-PYMT mice with DMXAA when posterior tumors reached ~ 6 mm in diameter (in approximately 2 month-old mice). Five days after the DMXAA injection, very few tumors (<20%) had regressed in MMTV-PyMT mice whereas 90% of Trans-PyMT tumors did regress, as shown for comparison in Fig. 1A . The detailed follow up of individual tumors of MMTV-PyMT mice ( Fig. 1B) shows that DMXAA reduced the tumor growth rate compared to control mice but tumor regression was rarely achieved.
We then examined the immune response triggered by DMXAA in Spont-PyMT tumors, compared to Trans-PyMT ones. Before treatment, the proportion of TAM (CD11b + Ly6C neg Ly6G neg F4/80 + ), monocytes (CD11b + Ly6C high Ly6G neg ), neutrophils (CD11b + Ly6G + ) and CD8 + T cells was similar between Trans-PyMT and Spont-PyMT tumors (Fig. 1C , grey bars). In both models, TAM represented the largest population of immune cells. After one injection of DMXAA, TAM, which are known to release TNFα early after DMXAA injection (Wang et al., 2009; Weiss et al., 2017) , decreased rapidly and came back close to their previous level at day 4 in spontaneous tumors compared to day 8 in transplanted ones (Fig. 1C ). Moreover, whereas DMXAA injection induced a strong and transient neutrophil infiltrate in Trans-PyMT at 24h (40% of the infiltrating cells), only a slight and transient infiltration (12% of the infiltrating cells) was measured in Spont-PyMT tumors. Monocytes arrived earlier in spontaneous tumors than in transplanted ones (day 1 versus day 4) but their numbers remained smaller. Finally, some CD8 + T cells were secondarily recruited in the tumor in the following days, and reached a peak at day 8 as in the DMXAA-treated Trans-PyMT tumors. However, this infiltrate was modest, about 4 times smaller than in Trans-PyMT tumors (8% versus 30% at day 8, respectively).
Altogether, these data indicate that DMXAA injection in Spont-PyMT tumors induced the recruitment of few neutrophils, monocytes and CD8 T cells, and led to a much smaller impact on tumor regression than in the transplanted tumor model.
MMTV-PyMT mice are resistant to STING-induced type I IFN production
Next, we reasoned that a difference in the tumor microenvironment could affect the cytokines and chemokines released after DMXAA injection. DMXAA activates the ubiquitous adaptor STING and subsequently triggers the production of TNFthrough NFB, the production of type I IFN through the phosphorylation of IRF3 (pIRF3) and the production of chemokines through pSTAT6 (Burdette and Vance, 2013; Roberts et al., 2007) . Thus, we measured the cytokines expressed in the tumor microenvironment shortly after DMXAA injection in MMTV-PyMT mice. As shown in figure 2A , we could detect the upregulation of TnfCcl2, Cxcl1 and Ccl20 in Spont-PyMT tumors, like in Trans-PyMT ones ( Fig. S1A ), even though the fold increases could be different in the two tumor types.
Strikingly, no significant increase in mRNA levels of Ifnand Ifngenes was detected in the spontaneous tumor model ( Fig. 2A ) whereas in transplanted tumors, these genes were highly expressed from 3h to 24h after DMXAA treatment ( Fig. S1A ). As expected, the absence of type I IFN transcripts led to an absence of IFN production in DMXAA-treated Spont-PyMT tumors, in contrast to Trans-PyMT ones (Fig. 2B ).
To test if the blunted type I IFN signaling after DMXAA injection in Spont-PyMT tumors is DMXAAspecific, we tested the TLR4 ligand LPS, another inducer of type I IFN. LPS injection induced Ifn, Ifnand Tnfα mRNA levels within 3 hours in Trans-PyMT tumors, while in Spont-PyMT tumors only TNFα gene was upregulated by LPS ( Fig. 2C) . Similarly, the intra-tumoral injection of the CDN 2'3' cGAMP, another STING agonist, failed to induce the upregulation of Ifnor Ifngenes in Spont-PyMT tumors (Fig. S1B ). These results indicate that Spont-PyMT tumors have an intrinsic, general impairment to produce type I IFN.
Taken together, these data show that Spont-PyMT tumors have an impaired production of type I IFN in response to STING or TLR4 stimulation, which may explain the resistance to DMXAA treatment in these mice.
DMXAA fails to induce the phosphorylation of IRF3 in Spont-PyMT tumors
We next analyzed early signaling triggered downstream of STING activation. In untreated mice, there was no difference in Sting, Irf3 and Irf7 mRNA levels between the two tumor models ( Fig.S2A ). The Tank binding kinase 1 (TBK1), which is responsible for the phosphorylation of IRF3, was phosphorylated in both tumor models after DMXAA treatment (Fig. S2B ). This result is consistent with the upregulation of Tnf and chemokines mRNA levels detected after DMXAA injection ( Fig. 2A ).
Together, this indicates that the signaling pathway leading to type I IFN production is altered downstream of TBK1 activation.
The phosphorylation of IRF3, involved in STING-as well as LPS-signaling pathways leading to type 1 IFN production, was first measured by immunofluorescence in tumor slices from transplanted and spontaneous tumors, as soon as 3h after DMXAA injection. A strong pIRF3 labeling (unraveling cell responsiveness to STING activation by DMXAA) was detected after DMXAA treatment in slices of Trans-PyMT tumors (Fig. 3A, left panel) . The pIRF3 + cells included tumor cells (EpCAM + ) and also myeloid cells (F4/80 + ) and some endothelial (CD31 + ) cells ( Fig. 3B ). By contrast, pIRF3 + cells were hardly detectable in tumor slices of DMXAA-treated Spont-PyMT tumors (Fig. 3A, right panel) . These results indicate that DMXAA injection failed to activate the IFN pathway in any cell type of the tumor ecosystem in MMTV-PyMT mice.
As DMXAA was first discovered as a vascular disrupting agent (Baguley and Siemann, 2010) , we wondered if the vasculature of Spont-PyMT tumors was resistant to vascular damages induced by DMXAA, thus preventing indirectly the activation of the immune infiltrate. In fact, after DMXAA injection, CD31 + vessels of Sont-PyMT tumors were rapidly disrupted, leading to a reduction in tumor perfusion ( Fig. S3 ) albeit to a lesser extent than in Trans-PyMT tumors (Weiss et al., 2017) . One can thus conclude that DMXAA does affect the Sont-PyMT tumor ecosystem, consistent with the production of chemokines and cytokines shown in Figure 2A . Nevertheless, the specific defect at the level of IFN production which normally contributes to the vascular damages (Roberts et al., 2008) is too weak to be really efficient in DMXAA-treated MMTV-PyMT mice.
To investigate more deeply if there was a difference in the tumor microenvironment between both tumors that could prevent the response to DMXAA, we transplanted cells freshly dissociated from Spont-PyMT tumors into a mammary gland of MMTV-PyMT mice starting to present spontaneous tumors. These mice therefore had one transplanted and several spontaneous tumors. We then checked whether IRF3 phosphorylation was prevented in all of them. About 10 days after tumor grafting, the PyMT transplanted tumor in these mice reached a diameter of  6mm. In these Trans-in-Spont PyMT tumors, DMXAA was able to trigger the phosphorylation of IRF3 at a level similar to that usually measured in Trans-PyMT tumors ( Fig. 3C and Fig. S2C ). At the same time, the Spont-PyMT tumor next to the transplanted one showed no pIRF3 labeling whatsoever (Fig. S2C ). These data indicate that the absence of DMXAA response in Spont-PyMT tumors is strictly due to its local microenvironment.
To further dissect which cell subset of the tumor microenvironment is important upon DMXAA stimulation, we first isolated tumor cells (EpCAM + ) from Trans-PyMT tumors, and measured the IFNα produced in response to DMXAA stimulation in vitro. No IFNα was detected ( Fig. S3D ), suggesting that immune infiltrating cells are likely to be the main source of IFN production in response to DMXAA. Then, we compared the capacity of CD45 + cells isolated from both Spont-and Trans-PyMT tumors to phosphorylate IRF3 after STING stimulation in vitro. We observed a profound reduction in the proportion of pIRF3 + cells amongst CD45 + cells in Spont-PYMT tumors (Fig. S2D ). We suspected that this maybe due to different CD45 + cell types which infiltrate Trans-PyMT and Spont-PyMT tumors at steady state. Even though the proportion of myeloid cells was equivalent in the two models, their phenotype was different. Indeed, compared to Trans-PyMT tumors, Spont-PyMT tumors contained much fewer activated (MHC II + ) TAM and monocytes ( Fig. 3E ), but twice as many CD206 + MHCII -TAM ( Fig. S2E ).
Taken together, these results suggest that although the two models are based on the same tumor cells, the tumor microenvironment of spontaneous MMTV-PyMT mice is resistant to DMXAA-induced IFN production. This resistance seems to be related mainly to the myeloid cell fraction.
TGF blocks type I IFN production by immune cells
TGFhas been shown to orientate myeloid cells towards immunosuppressive profiles and to inhibit the production of pro-inflammatory cytokines by macrophages, including IFN (Zhang et al., 2016) .
Therefore, we examined if TGF was involved in the impaired type I IFN production following DMXAA administration to MMTV-PyMT mice by changing the polarization of macrophages. Strikingly, TGFmRNA was expressed at much higher levels (~7 fold) in untreated Spont-PyMT tumors than in Trans-PyMT ones (Fig. 4A ). In addition, as shown in Figure 4B , the vast majority of the cells in spontaneous tumors, and not in transplanted ones, showed nuclear pSMAD2/3 expression, indicating active signaling through TGFR in Spont-PyMT tumors. Nuclear pSMAD 2/3 were found in all type of cells including F4/80 + myeloid cells as well as in gp38 + fibroblasts and EpCAM + tumor cells ( Fig. 4C ).
Next, we treated MMTV-PyMT mice with an anti-TGF antibody, and characterized the nature of immune cells in the tumors, before DMXAA treatment. We noticed that the proportion of neutrophils was increased by two fold among myeloid cells (20% versus <10% in anti-TGFversus control mice, respectively) at the expense of monocytes (Fig. S4A) . The proportion of TAM did not change, but their phenotype did. Indeed, blockade of TGF restored an activated profile with a doubling of MHCII + TAM (Fig. 5A) . The few infiltrating monocytes were also mainly MHC II + in anti-TGF treated mice.
We thus wondered if anti-TGFtreatment rendered Spont-PyMT tumors sensitive to DMXAA. To test this, MMTV-PyMT mice were treated with an anti-TGFantibody for 3 days, then injected with DMXAA and sacrificed 3h later, to measure the phosphorylation of IRF3 in tumor slices. As shown in Figure 5B , the neutralization of TGFin vivo allowed the DMXAA-induced phosphorylation of IRF3.
Among the pIRF3 + cells, we identified both F4/80 + myeloid cells and tumor cells. Moreover, this anti-TGFneutralization made possible the secretion of IFNafter DMXAA stimulation (Fig. 5C ). To identify if TAM were the cell population responsible for IFN production, we purified F4/80 + from dissociated tumors. It then appeared that the F4/80 + fraction produced a much larger amount of IFNcompared to the negative fraction of tumor cell suspension after in vitro stimulation with DMXAA ( Fig. 5D ). Furthermore, MHC II + subsets of TAM tend to produce more IFN than their MHC IIcounterpart (Fig. S4B ). Together, these results indicate that TGFtreatment renders MMTV-PyMT mice more sensitive to DMXAA stimulation by promoting the infiltration of mammary tumors by activated MHC II + TAM capable of producing type 1 IFN.
We next wondered if the blockade of TGF could facilitate tumor regression induced by DMXAA in those mice. Mice were treated with a combination of anti-TGFduring 9 days, associated with a single DMXAA injection, 3 days after the beginning of the TGF treatment. We observed that the majority of tumors had regressed or had stabilized at day 5 in mice receiving the combined treatment (Fig. 5E ). In addition, the non-regressing tumors grew more slowly than control or DMXAAtreated spontaneous mice.
All these results suggest that TGFacts on the proportion of immune cells able to produce type I IFN, and that blocking TGFallow DMXAA-induced IFN production and tumor regression in MMTV-PyMT mice.
Discussion
Type I IFN have the unique potential to promote the activation and recruitment of various immune effectors and represent a natural defense, mainly against viruses, which could be redirected against cancer. Encouraging results have already been obtained in transplanted tumor models with STING agonists (Corrales et al., 2015; Weiss et al., 2017) . However, whether one can induce therapeutically the production of type I IFN in spontaneous tumors remained a burning question. Here, we provide an example in which TGFβ accumulation in the microenvironment of spontaneous tumors prevents the production of IFNβ/α by macrophages after STING activation and contributes to block tumor rejection. This obstacle can be overcome with an anti-TGFβ treatment.
Truncated activation of the STING/TBK1/IRF3 pathway compromises regression of Spont-PyMT tumors
In stark contrast with the tumor regression systematically induced by DMXAA in transplanted PyMT mice (Weiss et al., 2017) , we report here that Spont-PyMT tumors rarely regress after STING activation. A weak immune response with few neutrophils, monocytes and CD8 + T cells recruited at the tumor site, was associated with the resistance to DMXAA-induced tumor regression. What was specifically lacking in spontaneous tumors was the production of IFNβ and IFNα, not the production of immune-attractant chemokines. Three type I IFN inducers, DMXAA, LPS or cGAMP, all failed to induce the production of IFNβ/α in these spontaneous tumors. These results suggest that a particular feature of spontaneous tumors may interfere with the induction of anti-tumor immunity and prompted us to look for specific blunted of ifnβ/α gene upregulation and production.
The absence of IFN mRNA was associated with a dramatic defect in IRF3 phosphorylation in the tumor ecosystem, in both tumor cells and immune infiltrating cells, after DMXAA injection in MMTV-PyMT mice. On the contrary, the activation of TBK1, necessary for the activation of IRF3, was preserved, indicating a specific block downstream STING/TBK1 pathway. The transcription of ifnβ, driven by pIRF3 homodimers or by pIRF3/pIRF7 heterodimers, was thus blocked at an early stage. A positive feedback loop mediated by IFNAR signaling normally allows further upregulation of IRF7 mRNA and IFN production. As expected, no upregulation of irf7 gene expression took place in Spont-PyMT tumors after DMXAA compared to Trans-PyMT tumors (data not shown), probably as a direct consequence of the absence of pIRF3 and IFNβ.
Decreased responsiveness to IFNα has already been reported in cancer patients (Critchley-Thorne et al., 2009) , with reduced phosphorylation of STAT1 after stimulation with IFNα in vitro. Our study adds a key element: next to the IFNα responsivess, the capacity to produce IFNβ and IFNα may also be compromised. Our study highlights that a defect in IFNβ/α production in a tumor may originate from an early block in STING/IRF3 signaling. This is different from the well-known defective IFNα production by tumor cells, as a result of mutations or epigenetic regulation of this pathway (Ng et al., 2018; Xia et al., 2016) , which provides an advantage for therapeutic interventions with oncoviruses (Xia et al., 2016) . Here, the therapeutic potential of STING agonists to boost an anti-tumor response in solid tumors relies on the capacity of the tumor microenvironment to produce type I IFN. The
MMTV-PyMT mammary model illustrates that some tumors may be resistant to such interventions.
Our data further suggest that it is the tumor microenvironment that conditioned the IFN/production the most, following DMXAA treatment. More specifically, endothelial cells and a large fraction of myeloid cells in Trans-PyMT tumors, strongly phosphorylated IRF3 following DMXAA injection. These results are consistent with earlier reports by Demaria and colleagues showing that endothelial cells rapidly produce IFNβ following injection of STING agonist (Demaria et al., 2015) .
Note however that in our experiments, endothelial cells were unlikely to be the main source of type I IFN as in Demaria's work, but represented only a minute fraction of pIRF3 + cells, susceptible to produce IFN. It should also be underlined that tumor cells were not producing IFNin vitro, which reveals the existence of an additional checkpoint between pIRF3 and IFNproduction. Together, our data therefore suggest that the different abilities of Trans-and Spont-PyMT to produce type I IFN resides in different tumor microenvironment, essentially in myeloid cells.
TGFβ impairs IFNβ/a production in the tumor microenvironment of Spont-PyMT
We found that an anti-TGFβ treatment allowed DMXAA to induce the activation of IRF3, the production of IFNα, and to facilitate tumor regression. TGFβ is fundamental in many physiological functions, including the regulation of mammary gland development. Although it may inhibit cell proliferation (and therefore, initial tumor growth), frequent mutations are found in TGFβR signaling that facilitate tumor outgrowth. However, TGFβ is better known for its negative role later on, with the suppression of immune effector functions and acceleration of metastasis dissemination (Moses and Barcellos-Hoff, 2011) . Not surprisingly, high levels of the active form of TGFβ have been associated with poor survival in many advanced cancer (Lin and Zhao, 2015) . Of particular interest, the density of pSMAD2/3 in the stroma, downstream TGFβR signaling, has been associated with poor prognosis in non-small cell lung cancer (Chen et al., 2014) . In MMTV-PyMT mice, the TGFβ mRNA level was high and nuclear pSMAD2/3 was observed in the vast majority of cells of the tumor ecosystem, indicating that the cellular source of TGF is unlikely to be unique. We have not attempted to identify the source of TGF, but it is well known that it may be secreted by multiple cell types, including macrophages (Mantovani et al., 2002) and apoptotic cells (Chen et al., 2001) . Such signs of massive TGFβ signalling were never observed in Trans-PyMT tumors. The fact that an anti-TGFβ treatment of MMTV-PyMT mice restored partially their capacity to respond to DMXAA for the production of type I IFN suggested that TGFβ signaling can directly or indirectly impair the activation of STING/TBK1/IRF3 pathway. One possibility is that SMAD2 and SMAD3 directly inhibit IRF3, resulting in reduced IFNproduction (Sugiyama et al., 2012) .
Another potential mode of action may be indirect. Indeed, it has been shown that TGFβR signaling is involved in the polarization of myeloid cells and the suppression of pro-inflammatory cytokines (Zhang et al., 2016) . Similarly, the blockade of TGF signaling promote the emergence of anti-tumoral neutrophils (Fridlender et al., 2009) . In our study, we found that the anti-TGFβ treatment was accompanied by an increased density of neutrophils and activated MHC II + TAM and monocytes that may be more prone to respond to pro-inflammatory signals. Interestingly, a human study conducted by Susuki and colleagues in human breast tumors showed that the plasmacytoid DC that accumulate in triple negative breast tumors, have a very low potency to produce type I IFN (Sisirak et al., 2012) , and TGFβ was involved in this blockade (Sisirak et al., 2013) .
Combination therapies with TGFβ blockade
Numerous studies have proposed explanations for the protumoral action of TGFβ. Many of them deal with the direct immunosuppressive effect of TGFβ (including their release by regulatory T cells) on T cells (Esquerré et al., 2008; Sarkar et al., 2011; Takaku et al., 2010) . Others attribute it to the polarization of myeloid cells towards an immunosuppressive phenotype (Zhang et al., 2016) , or to its effect on cancer-associated fibroblasts (Mariathasan et al., 2018; Tauriello et al., 2018) , and thus on the ability of T cells to contact tumor cells, even though the underlying molecular mechanism of inhibition remained elusive. We propose here a new molecular mechanism by which TGFβ may exert a protumoral effect, in particular in spontaneous tumors, in which TGFβ can blunt the IFNα/production. Our work demonstrates that the capacity of STING agonists to exert an anti-tumoral effect should be markedly enhanced if combined with an anti-TGFβ treatment. The TGF/IFN interference highlighted here is likely to matter not only for STING agonists under active development, but also for chemotherapeutic agents like anthracyclins, for which tumor regression has been associated with a type I IFN signature (Sistigu et al., 2014) . In tumors like breast tumors that poorly respond to anti-PD1/PDL1 checkpoint inhibitors, and in which TGF and M2-like macrophages are abundant (Fridman et al., 2017; Moses and Barcellos-Hoff, 2011) , our work shows that there would be a solid rationale for using a triple combination of anti-TGFβ, anti-PD-1 and a third partner, STING agonist or chemotherapy.
Experimental procedures
Animal studies MMTV-PyMT transgenic mice are maintained by backcrossing on FvB/NCrl mice (Charles River laboratories). Transplanted PYMT mice were generated as described in a previous work (Weiss et al,. 2017 ). Briefly, fresh tumor cell suspensions were prepared from MMTV-PyMT tumor bearing mice by mechanical and enzymatic dissociation and were then injected (10 6 cells) in one mammary gland of Tumor cell suspensions for in vitro experiments or flow cytometry characterization were prepared by mechanical and enzymatic dissociation (Weiss et al., 2017) .
Multicolor flow cytometry
Tumor cells suspension (4x10 6 ) were stained in 96-wells round bottom plates with live/dead staining (Blue fluorescent reactive dye, Invitrogen) during 20 minutes at room temperature. Fc receptors were blocked with anti-FcR (anti-CD16 CD-32 at 5µg/ml, BD Pharmingen). After 2 washes in PBS 2% FCS, cells were stained with the following antibodies CD45-AF700, CD11b-BV421, Ly6C-APCCy7, Ly6G-BV510, F4.80 BV650, IA/IE-BV785, CD206-PE, CD64-APC, CD11c-PeCy7 (for myeloid and MHC II staining), with CD45-AF700, TCRβ-BV605, CD4-BV711 and CD8-PerCPef710 antibodies (for lymphoid staining) antibodies, all purchased from BD Pharmingen. After washing in PBS, cells were fixed in 1% PFA, stored at 4°C, and acquired the next day with LSR II flow cytometer (BD Bioscience). For detection of phosphorylated proteins staining, cell suspensions were stimulated 3h with DMXAA 250µg/ml, fixed immediately in PFA 4%, permeabilized with frozen methanol 90%, stained overnight with pIRF3-AF647 or pTBK1-PE (from Ozyme), washed and analyzed by multicolor flow cytometry.
Immunofluorescence
Tumor pieces were fixed overnight with Periodate-Lysine-Paraformaldehyde at 4°C.
Immunofluorescence on thick tumor slices (350 µm) was performed as previously described (Bougherara et al., 2015) . Immunostaining of surface markers was performed at 37°C for 15 min with antibodies specific for EpCAM-BV421, F4/80-AF488 or AF647, Gp38-PEor CD31-PE (all from BD Pharmingen). For additional intracellular staining, tissue slices were fixed in 4% PFA (10min RT) and permeabilized with methanol 90% 30min at 4°C. For detection of pSMAD2/3, primary anti-pSMAD2/3
Ab was revealed with anti-rabbit Alexa 488 (cell signaling).
Images were obtained using a confocal spinning-disk (CSU-X1; Yokogawa) upright microscope (DM6000FS; Leica) equipped with a ORCA Flash4.0LT camera (Hamamatsu) and a 25x 0.95NA W objective (Leica). All images were acquired with MetaMorph 7 imaging software (Molecular Devices) and analyzed with Image J homemade routines.
Transcriptomic analysis
Tumor RNA was extracted using a RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. The RNA were reverse transcribed using the Advantage® RT for PCR kit (Applied system. The list of primers that were used are provided in the supplementary table 1.
ELISA
The IFN production test was performed on entire tumor cell suspensions obtained after Ficoll density separation (Histopaque-1093 from Sigma) or after cell sorting and then stimulated overnight with 250 µg/ml of DMXAA. The ELISA test was performed using IFN Mouse ELISA Kit (Thermo Fisher) according to the manufacturer's instructions. 
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